merestinib merestinib merestinib (ly2801653) is an experimental cancer drug in development by eli lilly. it is a small molecule inhibitor of met and several other receptor tyrosine kinases such as mst1r, flt3, axl, mertk, tek, ros1, ntrk1/2/3, and ddr1/2. merestinibinn: merestinibclinical dataroutes ofadministrationpoatc codenoneidentifiers iupac name n-(3-fluoro-4-phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide cas number1206799-15-6chemspider29361338unii5ogs5k699ekeggd11763chemical and physical dataformulac30h22f2n6o3molar mass552.542 g·mol−13d model (jsmol)interactive image smiles cc1ccc(c(=o)n1c2ccc(cc2)f)c(=o)nc3ccc(c(c3)f)oc4cc5cnn(c5cc4c6cnc6)c inchi inchi=1s/c30h22f2n6o3/c1-17-3-9-23(30(40)38(17)22-7-4-20(31)5-8-22)29(39)36-21-6-10-27(25(32)12-21)41-28-11-18-16-35-37(2)26(18)13-24(28)19-14-33-34-15-19/h3-16h,1-2h3,(h,33,34)(h,36,39)key:qhadvlvfmkeiip-uhfffaoysa-n meristinib is part of a phase ii clinical trial for advanced billiary tract cancer. the study is expected to be complete in april 2018. phase ii clinical trials for non-small cell lung cancer and solid tumors began in november 2016.